drugset / Trial / NCT03197012
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery. Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.
Timeline
- Start
- 2017-07-01
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATOC | Peptide | 111 mbq | — |
| Subject | 68Ga-DOTATOC | Peptide | 259 mbq | — |
| Subject | 90Y-DOTATOC | Peptide | 85 mbq | Other |
| Subject | 90Y-DOTATOC | Peptide | 115 mbq | Other |